Robert Hunter, III

Research Scientist

P: 205-581-2174

Contact
Close

Contact Robert Hunter, III

Robert (Bob) Hunter received his Bachelor of Science in chemistry from North Carolina State University. He joined Southern Research as a research scientist in the Chemistry Department in August 2016. Prior to joining SR, Hunter was a member of the medicinal chemistry group at GlaxoSmithKline that contributed to the discovery of VOTRIENT (Pazopanib) for the treatment of patients with advanced renal cell carcinoma. His primary research interest is the use of medicinal chemistry approaches to support drug discovery in the therapeutic areas of cancer, diabetes, obesity, and anti-virals. His experience includes high throughput hit-to-lead parallel synthesis techniques supporting early stage discovery through candidate selection of both small molecules and peptides. Some of Hunter’s other research contributions include the discovery of aza-stilbenes as potent and selective c-RAF inhibitors as a potential anti-cancer therapy; the discovery of isoquinolinyl pyridones as SGK1 inhibitors; and the discovery of novel GLP-1 peptide agonists demonstrating robust activity in vivo and superior metabolic stability. Hunter is co-author of 11 peer-reviewed scientific publications and co-inventor of nine patents.